IL-33 blockade prevents exacerbations in a model of chronic airway inflammation by blunting persistent inflammation and remodeling

J. Allinne (Tarrytown, United States of America), W. Lim (Tarrytown, United States of America), G. Scott (Tarrytown, United States of America), C. Sandén (Lund, Sweden), J. Erjefält (Lund, Sweden), D. Birchard (Tarrytown, United States of America), L. Ben (Tarrytown, United States of America), A. Murphy (Tarrytown, United States of America), M. Sleeman (Tarrytown, United States of America), J. Orengo (Tarrytown, United States of America)

Source: International Congress 2019 – Advances in asthma pharmacology
Session: Advances in asthma pharmacology
Session type: Poster Discussion
Number: 3876

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Allinne (Tarrytown, United States of America), W. Lim (Tarrytown, United States of America), G. Scott (Tarrytown, United States of America), C. Sandén (Lund, Sweden), J. Erjefält (Lund, Sweden), D. Birchard (Tarrytown, United States of America), L. Ben (Tarrytown, United States of America), A. Murphy (Tarrytown, United States of America), M. Sleeman (Tarrytown, United States of America), J. Orengo (Tarrytown, United States of America). IL-33 blockade prevents exacerbations in a model of chronic airway inflammation by blunting persistent inflammation and remodeling. 3876

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: